Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation monthly Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E48.99 EPS (ttm)2.49 Insider Own0.20% Shs Outstand786.06M Perf Week0.51%
Market Cap95.73B Forward P/E13.89 EPS next Y8.77 Insider Trans31.99% Shs Float775.87M Perf Month9.19%
Income2.00B PEG2.20 EPS next Q1.63 Inst Own79.80% Short Float0.95% Perf Quarter0.77%
Sales11.23B P/S8.52 EPS this Y28.10% Inst Trans1.34% Short Ratio1.75 Perf Half Y12.85%
Book/sh8.49 P/B14.34 EPS next Y21.47% ROA7.40% Target Price140.33 Perf Year17.81%
Cash/sh10.14 P/C12.01 EPS next 5Y22.28% ROE35.00% 52W Range94.39 - 127.00 Perf YTD5.21%
Dividend- P/FCF25.59 EPS past 5Y11.80% ROI11.70% 52W High-4.11% Beta1.76
Dividend %- Quick Ratio3.50 Sales past 5Y18.30% Gross Margin96.10% 52W Low29.02% ATR2.37
Employees7132 Current Ratio3.70 Sales Q/Q16.30% Oper. Margin25.00% RSI (14)61.55 Volatility2.20% 1.99%
OptionableYes Debt/Eq2.17 EPS Q/Q-22.20% Profit Margin17.80% Rel Volume1.00 Prev Close118.23
ShortableYes LT Debt/Eq2.09 EarningsJan 26 BMO Payout0.00% Avg Volume4.22M Price121.78
Recom1.80 SMA204.01% SMA504.34% SMA20011.07% Volume4,217,700 Change3.00%
Nov-09-16Downgrade Standpoint Research Buy → Hold
Nov-08-16Initiated Mizuho Buy $130
Jul-15-16Initiated Stifel Buy $138
Apr-29-16Reiterated Sun Trust Rbsn Humphrey Buy $145 → $147
Feb-25-16Initiated Citigroup Buy $130
Jan-20-16Initiated Credit Suisse Outperform
Jan-14-16Initiated Standpoint Research Buy $130
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $145
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Nov-06-15Reiterated UBS Buy $156 → $145
Oct-01-15Upgrade JP Morgan Neutral → Overweight
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $160
Jul-24-15Reiterated UBS Buy $142 → $156
Jul-24-15Reiterated JMP Securities Mkt Outperform $133 → $147
Jul-24-15Reiterated Cantor Fitzgerald Buy $146 → $163
Jul-21-15Reiterated Piper Jaffray Overweight $144 → $160
Jul-15-15Reiterated RBC Capital Mkts Outperform $135 → $150
Jul-15-15Reiterated Barclays Equal Weight $120 → $130
Feb-25-15Reiterated Argus Buy $130 → $155
Feb-27-17 08:23AM  Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
07:37AM  Why Vertex Expects Its Profit Margin to Rise in 2017
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conferences Business Wire
Feb-24-17 03:25PM  Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
01:45PM  Is There More Than Meets the Eye on Celgenes President, COO Retirement?
10:57AM  3 Incredibly Cheap Biotech Stocks at Motley Fool
05:43AM  REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation Business Wire
Feb-23-17 05:36PM  CELGENE CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
04:30PM  Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer Business Wire
02:20PM  Celgenes Revlimid Secures Label Expansion at Investopedia
08:02AM  Here's Why Celgene's Latest Drug Is So Exciting at Motley Fool
Feb-22-17 04:02PM  FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Business Wire
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb-21-17 07:01PM  3 Great Stocks to Buy Instead of NVIDIA Corporation at Motley Fool
08:15AM  Blog Coverage Celgene's Multiple Sclerosis Drug Reported Positive Phase-III Results Accesswire
06:00AM  [$$] US exporters line up behind tax code overhaul at Financial Times
Feb-20-17 10:30AM  Celgene MS Drug Reports Positive Phase 3 Data at Investopedia
08:24AM  3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter at Motley Fool
07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
Feb-19-17 11:41AM  Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands? at Motley Fool
Feb-17-17 04:15PM  Celgene MS Drug Wins In Trial; Will Safety Top Novartis, Biogen?
01:30PM  Stocks Quietly Mixed In Afternoon; Skyworks Breaks Out, Celgene Bases
08:39AM  Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial
08:14AM  CELGENE CORP /DE/ Files SEC form 8-K, Other Events
07:30AM  Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis Business Wire
Feb-16-17 02:39PM  3 Biotechs With Tremendously Promising Pipelines at Motley Fool
08:53AM  Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y
Feb-15-17 06:35PM  Cramer fires back at naysayers: Here's your proof that th...
06:22PM  Cramer fires back at naysayers: Here's your proof that this rally is real at CNBC
05:59PM  Proof the rally is real
01:04PM  CELGENE CORP /DE/ Financials
10:56AM  Celgene Could Have One More Powerful Move Higher
09:48AM  Want to Get In on Biotech? Check Out These 3 Stocks at Motley Fool
Feb-14-17 03:10PM  Some of biotech's biggest names have acquired this Md. company at bizjournals.com
10:28AM  3 Top Biotech Stocks to Buy on Sale at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
08:33AM  Celgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : February 14, 2017
Feb-13-17 03:52PM  Key Presenters At Leerink's Healthcare Conference
02:25PM  Regeneron: It's All Riding On Dupixent at Barrons.com
11:31AM  How one stock changed my life
09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb-10-17 04:14PM  Is Biogen a Risky Stock? at Motley Fool
12:01PM  3 Stocks We'd Buy and Hold for the Next 20 Years at Motley Fool
09:55AM  Major Biotechs Scare Off Loads of Short Sellers
08:38AM  Biotech ETFs Powered by Q4 Earnings
06:03AM  CELGENE CORP /DE/ Files SEC form 10-K, Annual Report
Feb-09-17 03:21PM  Why bluebird bio Stock Surged 20.7% Higher in January at Motley Fool
Feb-08-17 09:30AM  The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
08:23AM  Better Buy: Amgen Inc. vs. Celgene at Motley Fool
Feb-07-17 03:26PM  5 Great Biotech Stocks to Buy Now
09:06AM  Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More
07:41AM  4 Drug Stocks that are Broker Favorites
Feb-06-17 08:45AM  Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More
07:45AM  3 Stocks That Could Make You Rich at Motley Fool
Feb-03-17 10:32AM  ETFs with exposure to Celgene Corp. : February 3, 2017
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conference Business Wire
Feb-02-17 05:32PM  Biogen: What Now? at Barrons.com
04:23PM  Celgene Subsidiary Invests in Jounce Therapeutics
04:01PM  House Panel to Take Up Trump's Call to Speed FDA Approvals
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
08:02AM  What Could Make Biogen Crash? at Motley Fool
07:35AM  Understanding Celgenes Operational Performance Projections for 2017
07:27AM  Celgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : February 2, 2017
06:27AM  Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
Feb-01-17 04:12PM  Roche CEO Shrugs Off Trump's Drug Stance; 2016 Sales Narrowly Miss
03:17PM  Top Research Reports for February 1, 2017
10:36AM  Celgenes Big Plans for Otezla in 2017
09:30AM  The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals
09:06AM  Why Celgenes Otezla Is Expected to See Strong Demand Trends in 2017
07:36AM  Behind Celgenes Blockbuster Revenue Hit in 4Q16
07:14AM  Drug Stocks Rally on Trump Meet with Pharma Bigwigs
Jan-31-17 04:17PM  Fmr. Onyx CEO: Responsibility to find and research cures ...
12:34PM  Unusual activity: Bulls bet on Celgene & Potash
10:37AM  Celgenes Abraxane Sees Stable Demand in 4Q16
10:37AM  Trump, at Biopharma Meeting, Pledges to 'Streamline' FDA, Cut Regulations but Wants Lower Prices
10:33AM  Trump pushes drugmakers for lower prices, more U.S. production Reuters
10:15AM  4 Top Biotech Stocks With Big Upcoming Catalysts
09:07AM  Inside Celgenes Pomalyst: A Solid Growth Trend in 4Q16
07:38AM  Inside Celgenes Revlimid: Strong Patient Demand in 4Q16
07:30AM  7 Top Stocks to Buy in February at Motley Fool
06:43AM  4 FDA Decisions to Watch Out for in Feb 2017
Jan-30-17 04:05PM  Understanding Celgenes Robust Profit Margin Rise in 4Q16
02:36PM  Celgenes Financial Performance in 2016: Strong Growth in Volumes
12:54PM  Celgene Reported Robust Revenue Growth in 4Q16
10:20AM  Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid
09:40AM  Celgene Corp. :CELG-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017
08:22AM  3 Top Pharmaceutical Stocks to Buy in February at Motley Fool
Jan-28-17 12:01PM  How Big Is the Opportunity for Celgene's Otezla Overseas? at Motley Fool
08:28AM  3 Most Unbelievably Undervalued Biotech Stocks at Motley Fool
Jan-27-17 01:44PM  Celgene Corporation (CELG) To Acquire Autoimmune Firm Delinia For $775 Million at Insider Monkey
01:28PM  Celgene Corporation Continues Its Double-Digit Growth at Motley Fool
08:15AM  Blog Coverage Celgene Acquires Delinia; Set to Expand Inflammation and Immunology Portfolio Accesswire
07:17AM  Celgene Receives Positive CHMP Opinion to Expand REVLIMID® (Lenalidomide) Indication as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma (MM) after Autologous Stem Cell Transplantation Business Wire
06:15AM  Cambridges Jounce raises hopes as first Mass. biotech of 2017 to go public at bizjournals.com
01:24AM  Gilead Sciences Expected to Witness Drop in Revenues in 2017
Jan-26-17 08:12PM  Edited Transcript of CELG earnings conference call or presentation 26-Jan-17 2:00pm GMT
05:15PM  [$$] Celgene To Acquire Biotech Startup Delinia For Up to $775 Million at The Wall Street Journal
05:06PM  Celgene Aims To Hurdle Revlimid Patent Loss By Growing EPS Annually
04:41PM  Celgene's Fastest-Growing Drugs at Motley Fool
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc.; The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM
PEHL MICHAEL F.See remarksDec 02Option Exercise0.001,88001,880Dec 06 04:05 PM
Smith Scott AndrewSee RemarksDec 02Option Exercise0.003,750035,419Dec 06 04:05 PM
FOUSE JACQUALYN Asee remarksDec 02Option Exercise0.005,000084,392Dec 06 04:04 PM
Alles Mark JSee RemarksDec 02Option Exercise0.006,5600166,134Dec 06 04:03 PM
VESSEY RUPERTSee remarksNov 22Sale123.182,500307,9501,150Nov 30 04:15 PM
PEHL MICHAEL F.See remarksNov 10Option Exercise68.3920,4241,396,77022,052Nov 15 04:22 PM
PEHL MICHAEL F.See remarksNov 10Sale121.0422,0522,669,1490Nov 15 04:22 PM
Friedman Michael ADirectorNov 09Option Exercise31.8018,600591,48018,600Nov 10 04:14 PM
Friedman Michael ADirectorNov 09Sale116.1018,6002,159,4600Nov 10 04:14 PM
HUGIN ROBERT Jsee remarksNov 09Sale120.00100,00012,000,000922,201Nov 14 05:47 PM
CELGENE CORP /DE/10% OwnerOct 24Buy14.00800,15011,202,1004,834,980Oct 26 04:15 PM
CASEY MICHAEL DDirectorOct 18Option Exercise100.067,500750,45092,985Oct 19 04:16 PM
Friedman Michael ADirectorOct 03Option Exercise29.8656,1161,675,36456,116Oct 05 04:09 PM
Friedman Michael ADirectorOct 03Sale103.6656,1165,816,9850Oct 05 04:09 PM
BARKER RICHARD WDirectorSep 23Option Exercise36.9220,000738,40031,332Sep 26 04:08 PM
BARKER RICHARD WDirectorSep 23Sale110.8220,0002,216,40011,332Sep 26 04:08 PM
MARIO ERNESTDirectorSep 23Sale109.4215,0001,641,30090,058Sep 26 04:08 PM
KAPLAN GILLADirectorSep 19Option Exercise29.267,500219,45079,642Sep 20 04:42 PM
KAPLAN GILLADirectorSep 15Sale106.449,7101,033,53272,142Sep 16 04:15 PM
LOUGHLIN JAMES JDirectorAug 23Option Exercise26.3627,500724,85050,419Aug 24 04:28 PM
LOUGHLIN JAMES JDirectorAug 23Sale114.1027,5003,137,75022,919Aug 24 04:28 PM
CASEY MICHAEL DDirectorAug 22Sale114.0143,1344,917,70785,485Aug 23 04:29 PM
HUGIN ROBERT Jsee remarksJul 28Sale110.00100,00011,000,0001,022,201Aug 01 05:04 PM
MARIO ERNESTDirectorJul 01Option Exercise0.007330105,058Jul 05 04:32 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00733022,919Jul 05 04:30 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073300Jul 05 04:27 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00733081,852Jul 05 04:28 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00733023,146Jul 05 04:27 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00733011,551Jul 05 04:25 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073300Jul 05 04:26 PM
HUGIN ROBERT Jsee remarksJun 20Sale100.1675,0007,512,0001,122,201Jun 22 04:42 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333081,119Jun 17 04:18 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 17 04:13 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 17 04:14 PM
MARIO ERNESTDirectorJun 16Option Exercise0.002,0550113,892Jun 16 06:57 PM
COX CARRIE SMITHDirectorJun 16Option Exercise0.006,200022,413Jun 17 04:14 PM
KAPLAN GILLADirectorJun 15Option Exercise0.006,200080,786Jun 17 04:18 PM
LOUGHLIN JAMES JDirectorJun 12Option Exercise0.002,068021,853Jun 13 05:10 PM
MARIO ERNESTDirectorJun 12Option Exercise0.002,0680103,992Jun 13 05:10 PM
KAPLAN GILLADirectorJun 12Option Exercise0.002,068074,586Jun 13 05:09 PM
BARKER RICHARD WDirectorJun 12Option Exercise0.002,068011,439Jun 13 05:08 PM
CASEY MICHAEL DDirectorJun 12Option Exercise0.002,06800Jun 13 05:08 PM
Friedman Michael ADirectorJun 12Option Exercise0.002,06800Jun 13 05:09 PM
Alles Mark JSee RemarksApr 29Option Exercise0.0011,0000164,636May 03 04:30 PM
HUGIN ROBERT Jsee remarksApr 29Option Exercise0.0060,00001,228,311May 03 04:19 PM
Smith Scott AndrewSee RemarksApr 29Option Exercise0.0010,000036,656May 03 09:28 PM
MARIO ERNESTDirectorApr 26Option Exercise31.805,000158,975101,924Apr 28 04:09 PM
KAPLAN GILLADirectorApr 04Sale101.8415,9671,626,07972,518Apr 05 04:15 PM
BONNEY MICHAEL WDirectorMar 03Buy103.012,000206,0282,000Mar 04 04:33 PM